Australian Patent Office has granted patent in the ‘Sarnow’ patent series for microRNA-122 (miR-122) therapy for treatment of hepatitis C viral (HCV) infections to Regulus Therapeutics Inc which is a biopharmaceutical company leading the discovery and development of innovative drugs targeting microRNAs. This additional patent award will extend the reach of the Sarnow patent estate that already covers the use of an anti-miR inhibitor of miR-122 for the treatment of HCV in the United States and Europe to Australia also.
No comments:
Post a Comment